C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI (C1INHDGF)

Assessing Safety and Efficacy of Preoperative and Post-Transplant C1 Inhibitor (Berinert®) vs. Placebo in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on DGF and IRI

The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not receive C1INH treatment. Complement activation has been detected in animal models and human kidneys with ischemic reperfusion injury (IRI) and inflammatory cell infiltrates. By blocking complement activation the investigators hope to improve kidney graft function post transplant in these recipients.

Study Overview

• Status: Completed
• Conditions: End Stage Renal Disease; Ischemic Reperfusion Injury; Kidney Failure; Delayed Graft Function
• Intervention / Treatment: Drug: C1 Esterase Inhibitor; Drug: Placebo

Detailed Description

Early graft function has a long-term effect on graft survival. Poor early graft function and delayed graft function (DGF) contributes to decreased short- and long-term patient and graft survival, increased incidence of acute rejection, prolonged hospitalization, and higher costs of transplantation. Although multiple factors contribute to the impaired graft function, ischemia-reperfusion injury (IRI) is the underlying pathophysiology leading to poor early graft function and DGF. A >35% incidence of DGF has remained constant over time despite significant improvements in immunosuppressive strategies and patient management. This may be due to increased use of kidneys from "extended-criteria" and/or non-heart-beating donors, where even greater rates (>60%) of DGF have been reported.

More than 96,680 people are currently waiting for a kidney transplant in the United States (United Network for Organ Sharing (UNOS); UNOS.org 3/22/13). Of the 15,092 kidney transplants performed in the US in 2011, ~11,000 (62%) were from deceased donors. Of these, approximately 17% were from expanded-criteria donors. The USRDS reports that more than 50% of patients on the waiting list are willing to accept a kidney from an expanded-criteria donor (ECD) or donors after cardiac death (DCD).

From the investigators previous studies with C1INH (Berinert®) for prevention of antibody mediated rejection (ABMR), the investigators noted that no patients developed ABMR during treatment with C1INH, the investigators also noted a near significant reduction in DGF due to IRI (ClinicalTrials.gov(NCT01134510), FDA Investigational New Drug (IND#): 14363). These findings suggest an important role for complement in the mediation of IRI and that inhibition of early complement activation using C1INH in patients receiving at risk kidneys for IRI should reduce this costly and often devastating complication of kidney transplantation. In addition, numerous other studies in animal models have shown dramatic improvements in IRI models with the use of C1INH. Complement activation is detectable in animal and in human kidneys models after IRI and experimental data suggests that use of C1INH prior to induction of IRI significantly reduces IRI as well as inflammatory cell infiltrates. Based on this, the investigators hypothesize that the use of C1INH in patients receiving deceased donor (DD) kidney transplants with high risk for DGF will show significant reductions in DGF and improved outcomes post-transplant compared with patients receiving DD transplants who do not receive C1INH treatment. Here, the investigators propose to investigate the application of pre-operative and post-transplant doses of C1INH (Berinert®) vs. placebo in adult subjects receiving a DD renal allograft considered at high-risk for IRI and DGF. The investigators hypothesize that C1INH treated patients will demonstrate improved function of the kidney allograft compared to placebo, with equivalence in safety. The primary objectives of this study are: Using a double blinded, placebo controlled format, the investigators will:

1. Evaluate and compare the safety of C1INH (50 units/kilogram, round to the nearest 500 unit) administered pre-transplant and 24 hrs post-transplant in recipients of kidney allografts from high risk for IRI deceased donors.

The secondary objectives are to:

1. On the basis of safety and efficacy, determine appropriate Berinert® study dose for Phase III investigation, and
2. Determine appropriate endpoint choice for Phase III investigation.

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90048
      • Cedars-Sinai Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 18-70 yrs of age; recipient of ECD/DCD/ECD&DCD with risk index 3-8 for DGF based on specific criteria
• recipient who are ABO compatible with donor allograft
• pretransplant with meningococcal vaccination
• understand and sign a written consent prior to any study specific procedure.

Risk index (minimum 3- maximum 8):

DGF scale: Donor Age (<40yr = 0, 41-49yr = 1, 50-54yr = 2, 55-59yr = 3, >60yr=6), Cold Ischemia Time (0-12= 0, 13-18=1, 19-24=2, 24-30=3, 31-36=4, >37=6; Recipient Race (nonblack = 0, black =1); Donor death due to Cerebrovascular Accident (CVA) (donor age <50yrs = 0, donor age >50yrs = 3).

Exclusion Criteria:

• patients with known prothrombotic disorder (e.g. factor V leiden)
• history of thrombosis or hypercoagulable state excluding access clotting
• history of administration of C1INH containing products or recombinant C1INH within 15 days prior to study entry
• patients with known contraindication to treatment with C1INH
• patients with abnormal coagulation function (INR >2, partial thromboplastin time (PTT) > 50, platelets <80,000)
• who are not on anti-coagulation
• patients with known active presence of malignancies
• Polymerase chain reaction (PCR) positive for hep B/hep C/or HIV
• preemptive kidney transplantation recipient
• recipients of multi-organ transplants (kidney and any other organ)
• recipients of kidney allograft from DD who: cold ischemia time (CIT) <18h, terminal serum creatinine </= 1mg/dl, recipient of kidney allograft that was on pump preservation for any period prior to transplantation, recipient of kidney allograft from a living donor, female subject who are pregnant or lactating.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: C1-Inhibitor (Berinert) (Human) (C1INH); 35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.	Drug: C1 Esterase Inhibitor; C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses; Other Names: Berinert (C1INH)
Placebo Comparator: Normal Saline; 35 patients will receive placebo in addition to standard of care immunosuppressive therapy.	Drug: Placebo; Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses; Other Names: Normal Saline (0.9%NaCl)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5.	Number of participants in the C1INH and placebo groups with serum creatinine >3mg/dL on postoperative day 5	First 7 days post-transplant
Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant.	The proportion of patients enrolled who require at least one session of dialysis in the first 7 days post transplant (excluding those who are dialyzed for hyperkalemia).	First 7 days post-transplant
Number of Patients With Serum Creatinine Reduction Ratio of < 30% From 24 to 48 Hours Post-transplant.	Number of patients in the C1INH and placebo groups with serum creatinine reduction of < 30% from 24 to 48 hours post-transplant.	First 7 days post-transplant
Number of Dialysis Sessions Per Patient in the First 7 Days Post Transplant.	Mean quantity of dialysis sessions per patient in the first 7 days post transplant.	First 7 days post-transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum Creatinine	Mean serum creatinine on day 90 in mg/dL	Up to 90 days post-transplant
Creatinine Clearance	Creatinine clearance calculated based on serum creatinine, milliliters per minute.	Up to 90 days post-transplant
24h Urine Output	24 hour urine output post-transplantation measured in milliliters	24 hours post-transplant
Mean Number of Patients on Dialysis	Mean number of patients on dialysis at 15 to 30 days post-transplant	15 to 30 days post-transplantation
Number of Patients With Delayed Graft Function (DGF) (Categorized by DGF Scale)	DGF Scale: Grade 1 - immediate urine production and no need for dialysis with creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation >70% Grade 2 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of >70% with need for dialysis Grade 3 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation <70% with no need for dialysis Grade 4 - creatinine reduction ratio (CRR) between time 0 of transplantation and day 7 post-transplantation of <70% with need for dialysis.	First 7 days post-transplant

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Incidence of Serious Adverse Events	Overall incidence of serious adverse events in the C1INH and placebo groups, number of events.	Up to 9 months post-transplant
Patient Survival	Patient survival at 90 days post-transplantation	Up to 90 days post-transplant
Rate of Acute Cellular Rejection (ACR)	Number of acute cellular and antibody mediated rejection episodes by day 90.	Up to 90 days post-transplant
Graft Survival	Number of Participants with Graft Survival at 90 Days Post-Transplant	Day 90 Post-transplant

Collaborators and Investigators

• Sponsor: Cedars-Sinai Medical Center
• Investigators: Principal Investigator: Stanley C Jordan, MD, Cedars-Sinai Medical Center, Los Angeles, CA; Study Director: Ashley Vo, PharmD, Cedars-Sinai Medical Center, Los Angeles, CA

Publications and helpful links

General Publications

• Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, Divella C, Battaglia M, Lucarelli G, Annunziata G, Palazzo S, Selvaggi FP, Staffieri F, Crovace A, Daha MR, Mannesse M, van Wetering S, Paolo Schena F, Grandaliano G. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010 Apr;176(4):1648-59. doi: 10.2353/ajpath.2010.090276. Epub 2010 Feb 11.
• Dalle Lucca JJ, Li Y, Simovic M, Pusateri AE, Falabella M, Dubick MA, Tsokos GC. Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage. Shock. 2012 Jul;38(1):82-91. doi: 10.1097/SHK.0b013e31825a3522.
• Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis. 2008 Sep;52(3):553-86. doi: 10.1053/j.ajkd.2008.06.005.
• Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blancho G, Daguin P, Ancelet D, Soulillou JP. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int. 1998 Sep;54(3):972-8. doi: 10.1046/j.1523-1755.1998.00071.x.

Helpful Links

• Cedars Sinai Medical Center Kidney Transplantation
• Information of C1INH (Berinert)

Study record dates

Study Major Dates

• Study Start: September 1, 2014
• Primary Completion (Actual): March 13, 2017
• Study Completion (Actual): March 13, 2017

Study Registration Dates

• First Submitted: February 19, 2014
• First Submitted That Met QC Criteria: May 8, 2014
• First Posted (Estimate): May 9, 2014

Study Record Updates

• Last Update Posted (Actual): June 25, 2018
• Last Update Submitted That Met QC Criteria: June 20, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Keywords: chronic kidney disease; Kidney Transplant; end stage renal disease; delayed graft function; ECD; ESRD (End Stage Renal Disease); CKD (Chronic Kidney Disease); expanded-criteria donor
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Urologic Diseases; Postoperative Complications; Renal Insufficiency, Chronic; Kidney Diseases; Kidney Failure, Chronic; Renal Insufficiency; Reperfusion Injury; Delayed Graft Function; Physiological Effects of Drugs; Immunosuppressive Agents; Immunologic Factors; Complement Inactivating Agents; Complement C1 Inhibitor Protein; Complement C1 Inactivator Proteins; Complement C1s
• Other Study ID Numbers: C1INH (Berinert) for DGF; IND15806 (Other Identifier: FDA)